A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

Inclusion Criteria: * Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired * Have low circulating levels of testosterone * Have low circulating levels of gonadotropins (follicle stimulating hormone \[FSH\]; luteinizing hormone) * Presence of both scrotal testes * Have azoospermia (no measurable level of sperm) * Adequate replacement of other pituitary hormones * Good general physical and mental health Exclusion Criteria: * Primary hypogonadism, such as Klinefelter's syndrome * History of unilateral or bilateral cryptorchidism (maldescended testes) * History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy * Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months * Proven spermatogenesis with hCG treatment alone * Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis * Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels * Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study * History or presence (known or suspected) of testicular, prostatic or breast cancer * Prostate pathology of clinical importance…